Research Study

Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF)
Principal Investigator 
Anthony Y-F. Fung

Overview

Body Locations and Systems 
Disorders and Conditions 
Mild Cognitive Impairment
ClinicalTrials.gov# 
NCT02387229
Status 
Recruiting
Study Start/End 
Sep 1, 2015 to Sep 1, 2020
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Andrew Starovoytov, Research Nurse
Phone 
604-875-5079
Purpose of Study 

This is a prospective, multicenter, randomized, double-blinded clinical trial exploring the efficacy and safety of rivaroxaban as compared to acetylsalicylic acid in reducing stroke, transient ischemic attack (TIA) and neurocognitive decline, in subjects with non-valvular AF and with low risk of stroke.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.